NASDAQ:JNP - Juniper Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.50 +0.03 (+0.26 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$11.50
Today's Range$11.45 - $11.50
52-Week Range$4.30 - $13.25
Volume28,513 shs
Average Volume155,873 shs
Market Capitalization$129.89 million
P/E Ratio-76.67
Dividend YieldN/A
Juniper Pharmaceuticals logoJuniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

Receive JNP News and Ratings via Email

Sign-up to receive the latest news and ratings for JNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.06
Current Ratio2.57
Quick Ratio2.18


Trailing P/E Ratio-76.67
Forward P/E Ratio76.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$49.98 million
Price / Sales2.60
Cash Flow$0.0176 per share
Price / Cash654.93
Book Value$3.83 per share
Price / Book3.00


EPS (Most Recent Fiscal Year)($0.15)
Net Income$-2,060,000.00
Net Margins-1.77%
Return on Equity-1.09%
Return on Assets-0.77%


Outstanding Shares11,320,000
Market Cap$129.89 million

Juniper Pharmaceuticals (NASDAQ:JNP) Frequently Asked Questions

What is Juniper Pharmaceuticals' stock symbol?

Juniper Pharmaceuticals trades on the NASDAQ under the ticker symbol "JNP."

How were Juniper Pharmaceuticals' earnings last quarter?

Juniper Pharmaceuticals Inc (NASDAQ:JNP) released its quarterly earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.04 by $0.18. The specialty pharmaceutical company earned $15.31 million during the quarter, compared to the consensus estimate of $16.30 million. Juniper Pharmaceuticals had a negative net margin of 1.77% and a negative return on equity of 1.09%. View Juniper Pharmaceuticals' Earnings History.

When is Juniper Pharmaceuticals' next earnings date?

Juniper Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Juniper Pharmaceuticals.

What price target have analysts set for JNP?

2 brokerages have issued 12 month price targets for Juniper Pharmaceuticals' shares. Their forecasts range from $24.00 to $24.00. On average, they anticipate Juniper Pharmaceuticals' share price to reach $24.00 in the next year. This suggests a possible upside of 108.7% from the stock's current price. View Analyst Price Targets for Juniper Pharmaceuticals.

What is the consensus analysts' recommendation for Juniper Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Juniper Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Juniper Pharmaceuticals.

Who are some of Juniper Pharmaceuticals' key competitors?

Who are Juniper Pharmaceuticals' key executives?

Juniper Pharmaceuticals' management team includes the folowing people:
  • Ms. Alicia Secor, Pres, CEO & Director (Age 55)
  • Mr. Jeffrey E. Young, CFO, Sr. VP of Fin., Treasurer & Sec. (Age 45)
  • Dr. Nikin Patel, COO & Director (Age 45)
  • Dr. Shen Luk BSc, Ph.D., Chief Scientific Officer
  • Dr. Claire Madden-Smith BSc, Ph.D., Sr. VP of Juniper Pharma Services

Has Juniper Pharmaceuticals been receiving favorable news coverage?

News coverage about JNP stock has trended positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Juniper Pharmaceuticals earned a news and rumor sentiment score of 0.28 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 48.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Juniper Pharmaceuticals.

Who are Juniper Pharmaceuticals' major shareholders?

Juniper Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.78%), BlackRock Inc. (3.78%), Acadian Asset Management LLC (2.48%), Algert Global LLC (2.30%), Municipal Employees Retirement System of Michigan (2.05%) and Dimensional Fund Advisors LP (2.04%). Company insiders that own Juniper Pharmaceuticals stock include Alicia Secor, C Ann Merrifield, George Elston and James A Geraghty. View Institutional Ownership Trends for Juniper Pharmaceuticals.

Which institutional investors are selling Juniper Pharmaceuticals stock?

JNP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Municipal Employees Retirement System of Michigan, Macquarie Group Ltd., Heartland Advisors Inc., Globeflex Capital L P and Algert Global LLC. View Insider Buying and Selling for Juniper Pharmaceuticals.

Which institutional investors are buying Juniper Pharmaceuticals stock?

JNP stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP and Spark Investment Management LLC. Company insiders that have bought Juniper Pharmaceuticals stock in the last two years include Alicia Secor, C Ann Merrifield, George Elston and James A Geraghty. View Insider Buying and Selling for Juniper Pharmaceuticals.

How do I buy shares of Juniper Pharmaceuticals?

Shares of JNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juniper Pharmaceuticals' stock price today?

One share of JNP stock can currently be purchased for approximately $11.50.

How big of a company is Juniper Pharmaceuticals?

Juniper Pharmaceuticals has a market capitalization of $129.89 million and generates $49.98 million in revenue each year. The specialty pharmaceutical company earns $-2,060,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Juniper Pharmaceuticals employs 155 workers across the globe.

How can I contact Juniper Pharmaceuticals?

Juniper Pharmaceuticals' mailing address is 33 Arch Street, Boston MA, 02110. The specialty pharmaceutical company can be reached via phone at 617-639-1500 or via email at [email protected]

MarketBeat Community Rating for Juniper Pharmaceuticals (NASDAQ JNP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Juniper Pharmaceuticals and other stocks. Vote "Outperform" if you believe JNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.